Location History:
- Chestnut Hill, MA (US) (2013)
- Wellesley, MA (US) (2018 - 2022)
- Boston, MA (US) (2024)
Company Filing History:
4 out of 1,210 
2 out of 3,685 
1 out of 8,384 
Years Active: 2013-2024
Title: Innovations and Contributions of Irene M Ghobrial
Introduction
Irene M Ghobrial is a prominent inventor based in Wellesley, MA (US), known for her significant contributions to the field of biomedical research. She holds a total of six patents, showcasing her innovative approach to addressing complex medical challenges. Her work primarily focuses on developing therapeutic strategies for various diseases, including Waldenstrom's macroglobulinemia.
Latest Patents
One of her latest patents is centered around proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof. This patent discloses multifunctional compounds, conjugates, macromolecules, and polymers that target dysregulated proteins for degradation. Additionally, it includes methods of preparation, compositions, kits, and methods of use relating to these degraders. Another notable patent involves the treatment of Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody. This disclosure provides a method for treating subjects afflicted with this condition by administering a therapeutically effective amount of an antibody that specifically binds to the CXCR4 receptor expressed on the surface of WM cells.
Career Highlights
Irene has worked with esteemed organizations such as Dana-Farber Cancer Institute Inc. and Bristol-Myers Squibb Company. Her experience in these institutions has allowed her to contribute to groundbreaking research and development in the field of cancer treatment.
Collaborations
Irene has collaborated with notable colleagues, including Aldo M Roccaro and Josephine M Cardarelli. These partnerships have further enhanced her research capabilities and have led to significant advancements in her field.
Conclusion
Irene M Ghobrial's innovative work and dedication to medical research have made her a key figure in the development of new therapeutic strategies. Her patents reflect her commitment to improving patient outcomes and advancing scientific knowledge.